Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9UBC1
UPID:
IKBL1_HUMAN
Alternative names:
Inhibitor of kappa B-like protein; Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor-like 1
Alternative UPACC:
Q9UBC1; A6NL91; B4DUW1; Q14625; Q5HYU4; Q5RJ72; Q5ST96; Q5STV4; Q5STV5; Q9UBX4
Background:
NF-kappa-B inhibitor-like protein 1, also known as Inhibitor of kappa B-like protein, plays a pivotal role in the regulation of the innate immune response. It acts as a negative regulator of Toll-like receptor and interferon-regulatory factor signaling pathways, contributing to the suppression of NF-kappa-B target genes activation in response to proinflammatory stimuli.
Therapeutic significance:
Given its involvement in Rheumatoid arthritis, a disease characterized by autoimmune features and complex genetic components affecting joints, NF-kappa-B inhibitor-like protein 1 presents a promising target for therapeutic intervention. Understanding its role could lead to novel strategies in managing this debilitating condition.